Genentech, Inc. v. Insmed Incorporation

442 F. Supp. 2d 838, 2006 WL 2336484
CourtDistrict Court, N.D. California
DecidedAugust 10, 2006
DocketC-04-5429 CW (EMC)
StatusPublished
Cited by8 cases

This text of 442 F. Supp. 2d 838 (Genentech, Inc. v. Insmed Incorporation) is published on Counsel Stack Legal Research, covering District Court, N.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Genentech, Inc. v. Insmed Incorporation, 442 F. Supp. 2d 838, 2006 WL 2336484 (N.D. Cal. 2006).

Opinion

ORDER GRANTING IN PART AND DENYING IN PART PLAINTIFFS’ MOTION ON SCOPE AND PROCEDURE OF WILLFULNESS DISCOVERY; AND GRANTING IN PART AND DENYING IN PART DEFENDANTS’ CROSS-MOTION TO QUASH OR LIMIT SCOPE OF SUBPOENAS (Docket Nos. 514, 524)

CHEN, United States Magistrate Judge.

Plaintiffs have sued Defendants for patent infringement and a declaratory judg *839 ment of patent infringement. On July 17, 2006, Defendants decided that they would assert the advice-of-counsel defense with respect to the claim of willful infringement. Currently pending is Plaintiffs’ motion on the scope and procedure of willfulness discovery and Defendants’ cross-motion to quash or limit the scope of subpoenas. Having reviewed the parties’ briefs and accompanying submissions, and good cause appearing therefor, the Court hereby GRANTS in PART and DENIES in PART each party’s motion.

I. FACTUAL & PROCEDURAL BACKGROUND

On December 23, 2004, Plaintiffs filed suit against Defendants. In their original complaint, Plaintiffs asserted claims for infringement of the '151 patent and for a declaratory judgment of infringement of the '151 and '414 patents. The claim for declaratory relief “was aimed primarily at Insmed’s intended future conduct to infringe once it received FDA approval of its iPlexTM product.” Mot. at 5.

Approximately a year later, in December 2005, the FDA approved the .iPlexTM product. See id. Subsequently, in May 2006, Defendants launched the product. See id. Approximately a month later, on June 30, 2006, Judge Wilken issued her claim construction order. See Docket No. 510. In that same order, Judge Wilken granted Plaintiffs’ motion for partial summary judgment, holding that Defendants infringed claims 1, 2, and 9 of the '414 patent and that the '151 patent is not invalidated by the Maack and Sommer abstracts. Per this Court’s prior ruling, see Docket No. 258, Defendants then had fifteen days to make a decision as to whether they would rely on an opinion of counsel as part of a defense to Plaintiffs’ claim, of willful infringement. On July 17, 2006, Defendants decided that they would assert the advice-of-counsel defense.

Accordingly, on the same day, Defendants produced to Plaintiffs documents related to opinions from various law firms, including Foley & Lardner (“Foley”) who is also trial counsel in this case. With respect to Foley, three formal opinions were given. First, on October 21, 2002, Foley provided an opinion on invalidity of the '414 patent. See Shiang Deck, Ex. 8. Second, on December 2, 2002, Foley provided an opinion on infringement with respect to the '151 patent. See Shiang Deck, Ex. 1. Finally, in or about February 2005, Foley provided an update on the infringement opinion. See id., Ex. 2. Beth Bur-rous was the author of the formal opinions. See Burrous Deck ¶4 (“As intellectual property counsel for Insmed I prepared opinion letters for Insmed related to the U.S. Patent Nos. 6,331,414 and 5,187,151 that I understand have been produced in this case.”). Brian McCaslin assisted with the preparation of the formal opinions. See McCaslin Deck ¶ 4.

Apparently, even after Judge Wilken’s order in which she held that Defendants infringed three claims of the '414 patent, Defendants continued to market the iPlexTM product. See Reply at 1-2.

II. DISCUSSION

Currently pending before the Court is Plaintiffs’ motion on the scope and procedure of willfulness discovery and Defendants’ cross-motion to quash or limit the scope of subpoenas. There are three issues raised in Plaintiffs’ motion: (1) whether Defendants’ waiver of attorney-client privilege (because of their assertion of the advice-of-counsel defense) should extend to advice given by Foley as trial counsel; (2) whether Plaintiffs should be permitted to take six additional depositions as part of willfulness discovery and re *840 open two depositions; and (3) whether the scope of willfulness discovery should be limited to the documents that Defendants produced to Plaintiffs on July 17, 2006. In turn, Defendants’ motion raises the question of what discovery should be permitted with respect to Plaintiffs’ subpoenas directed to three law firms — namely, Foley, WilmerHale (formerly Hale & Dorr), and Sterne, Kessler, Goldstein & Fox — who provided opinions on the patents at issue.

A. Advice from Foley

1. EchoStar

Federal Circuit law governs the issue of privilege and discoverability arising from assertion of the advice-of-counsel defense. See In re EchoStar Comms. Corp., 448 F.3d 1294, 1298 (Fed. Cir.2006) (“[Qjuestions of privilege and discoverability that arise from assertion of the advice-of-counsel defense necessarily involve issues of substantive patent law.”). Plaintiffs argue that, because Defendants have asserted the advice-of-counsel defense, Plaintiffs are entitled to all advice given by Foley which would include (1) advice provided as trial counsel, not just opinion counsel, and (2) advice provided after the filing date of the complaint, especially since infringement by Defendants did not occur until after the complaint was filed and Defendants continued to sell the iPlexTM product even after Judge Wilken’s order finding infringement. Plaintiffs assert that the above is justified in light of the recent Federal Circuit opinion In re EchoStar.

In response, Defendants claim that they have produced documents that came after the filing of the complaint consisting of communications between opinion counsel and Defendants, see Opp'n at 11 n. 3, so that the only issue here is whether waiver should extend to trial counsel. Defendants argue that EchoStar did not address this specific issue. Defendants further argue that Foley opinion counsel was walled off from the Foley trial team and thus should be treated separately.

There does not appear to be any dispute that Defendants have, as they assert, produced documents that post-date the complaint to the extent they involve opinion counsel. Thus, as Defendants contend, the only question for the Court is whether the waiver by Defendants, because of their assertion of the advice-of-counsel defense, should reach trial counsel. 1 The burden is on Defendants to establish nonwaiver. See In re Regents of the Univ. of Cal., 101 F.3d 1386, 1390 n. 2 (Fed.Cir.1996) (“For procedural matters that are not unique to patent issues, we apply the perceived law of the regional circuit.”); United States v. Martin, 278 F.3d 988

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Lifenet, Inc. v. Musculoskeletal Transplant Foundation, Inc.
490 F. Supp. 2d 681 (E.D. Virginia, 2007)
Celerity, Inc. v. Ultra Clean Holding, Inc.
476 F. Supp. 2d 1159 (N.D. California, 2007)
Autobytel, Inc. v. Dealix Corp.
455 F. Supp. 2d 569 (E.D. Texas, 2006)

Cite This Page — Counsel Stack

Bluebook (online)
442 F. Supp. 2d 838, 2006 WL 2336484, Counsel Stack Legal Research, https://law.counselstack.com/opinion/genentech-inc-v-insmed-incorporation-cand-2006.